Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8913

Target Organs and Levels of Evidence for TR-358

Toxicology and Carcinogenesis Studies of Ochratoxin A (CASRN 303-47-9) in F344/N Rats (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
Ochratoxin A
303-47-9
04/18/1988 Gavage
R: 0, 21, 70, 210 MG/KG
Battelle Columbus Laboratory

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Tubular Cell: ADENOMA 1/50 1/51 6/51 10/50 OR CARCINOMA 0/50 0/51 16/51 30/50
Non-Neoplastic Lesions
  • KIDNEY: RENAL TUBULE, EPITHELIUM, HYPERPLASIA 1/50 1/51 16/51 24/50, PROLIFERATION 0/50 0/51 10/51 26/50, CYTOPLASMIC ALTERATION 1/50 0/51 3/51 8/50, KARYOMEGALY 0/50 1/51 51/51 50/50, DEGENERATION 0/50 0/51 50/51 49/50
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Tubular Cell: ADENOMA 0/50 0/51 1/50 5/50 OR CARCINOMA 0/50 0/51 1/50 3/50
  • Mammary Gland: FIBROADENOMA 17/50 23/51 22/50 28/50
Non-Neoplastic Lesions
  • KIDNEY: RENAL TUBULE, EPITHELIUM, HYPERPLASIA 0/50 0/51 12/50 13/50, PROLIFERATION 0/50 0/51 3/50 16/50, KARYOMEGALY 0/50 8/51 50/50 50/50, DEGENERATION 0/50 0/51 49/50 49/50